Business
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Philadelphia-based Mineralys Therapeutics launched today with a $40 million Series A round to move its clinical asset, MLS-101, into Phase II testing for hypertension.
The biopharmaceutical industry saw two CEO appointments made today, including Howard J. Federoff, M.D., Ph.D., to Brooklyn ImmunoTherapeutics and Eric Koo to Overland ADCT BioPharma.
Gilead CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home.
The New York-based company inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced its seed funding round was extended from $12 million to $44 million.
Valence Discovery just announced a strategic alliance with Charles River Laboratories to make its artificial intelligence (AI) and machine learning (ML) platform available to Charles River’s clients.
Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.
He’ll make a return to his former role at SV Health Investors as a Venture Partner.
The San Jose BioCube life sciences incubator project has undergone a significant renovation that includes a major expansion of its headquarter facilities and also provides housing for new life sciences startups.
If you’re one of the 17% of Americans that have been fully vaccinated against SARS-CoV-2, you are probably feeling some level of relief. But the CDC warns not to throw your mask away just yet.
It’s something of the holy grail—run whole genome sequencing on a sample of a person’s blood and identify their risk for disease, all quickly and affordably. Oxford, England’s Genomics, founded in 2014 out of Oxford University by Sir Peter Donnelly, may be getting close.